[Expression of matrix metalloproteinase-9 and its complex in the urine of breast cancer patients].
OBJECTIVE
To investigate the expression and clinical significance of matrix metalloproteinase-9 and its complex in the urine of the patient with breast cancer.


METHODS
Using substract gel electrophoresis and western-blot analysis, expressions of MMP-9 and MMP-9/NGAL complex in breast cancer (n = 97), breast benign (n = 41) and normal (n = 60) were observed.


RESULTS
There MMP-9 and MMP-9/NGAL complex expressions were 76.29% and 64.95% in breast cancer, 46.34% and 43.90% in breast benign, and 23.33% in normal respectively. The MMP-9 and MMP-9/NGAL complex expressions were higher in breast cancer than those in breast benign and in normal (chi(2) = 7.456, P < 0.01). MMP-9 and MMP-9/NGAL complex expressions in urine of breast cancer had not any relationship with tumor size, TNM stage, patient age, menopause status as well as ER status, but was correlated to lymphatic node status (chi(2) = 5.206, P < 0.05).


CONCLUSIONS
MMP-9 and MMP-9/NGAL complex expressions in urine are significant in estimating lymphatic node metastasis in breast cancer and a valuable early prognostic factors and screening in breast cancer.
Shen
Zhe-zhu
ZZ
Department of Surgery, College of Clinical Oncology, Beijing Medical University, Beijing 100036, China.
Zhao
Wei
W
Gu
Jin
J
Zhang
Zhi-qian
ZQ
Yan
Li
L
D000209:Acute-Phase Proteins; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000473:pathology / Q000652:urine*; D002352:Carrier Proteins / Q000652:urine*; D005260:Female; D006801:Humans; D000071068:Lipocalin-2; D054834:Lipocalins; D008207:Lymphatic Metastasis; D020780:Matrix Metalloproteinase 9 / Q000652:urine*; D015513:Oncogene Proteins; D011518:Proto-Oncogene Proteins
D000209:Acute-Phase Proteins; D002352:Carrier Proteins; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D015513:Oncogene Proteins; D011518:Proto-Oncogene Proteins; D020780:Matrix Metalloproteinase 9